Anoro Ellipta

Anoro Ellipta

umeclidinium + vilanterol

Manufacturer:

GlaxoSmithKline

Distributor:

GlaxoSmithKline
Concise Prescribing Info
Contents
Per 62.5 mcg/25 mcg DPI Umeclidinium Br 62.5 mcg (equiv to 55 mcg), vilanterol trifenatate 25 mcg (equiv to 22 mcg)
Indications/Uses
Maintenance bronchodilator treatment to relieve symptoms associated w/ COPD.
Dosage/Direction for Use
Adult 1 inhalation once daily at the same time each day.
Contraindications
Special Precautions
Not recommended in patients w/ asthma. Not for the relief of acute symptoms ie, rescue therapy for the treatment of bronchospasm. Discontinue use if paradoxical bronchospasm occurs. Severe CV disease; narrow-angle glaucoma or urinary retention. Pregnancy & lactation. Childn <18 yr.
Adverse Reactions
UTI, sinusitis, nasopharyngitis, pharyngitis, upper resp tract infection; cough, oropharyngeal pain; constipation, dry mouth.
Drug Interactions
Vilanterol: May weaken or antagonize effect w/ either nonselective or selective β-adrenergic blockers. Increased systemic exposure w/ strong CYP3A4 inhibitors (eg, ketoconazole).
MIMS Class
Antiasthmatic & COPD Preparations
ATC Classification
R03AL03 - vilanterol and umeclidinium bromide ; Belongs to the class of combination of adrenergics with anticholinergics, that may also include a corticosteroid. Used in the treatment of obstructive airway diseases.
Presentation/Packing
Form
Anoro Ellipta 62.5 mcg/25 mcg DPI
Packing/Price
30 dose x 1's
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in